

## **Betamethasone Ointment Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.0	06.04.2024	1842048-00016	Date of first issue: 19.07.2017

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Betamethasone Ointment Formulation
1.2	Relevant identified uses of th	ne s	substance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	Organon & Co. 30 Hudson Street, 33nd floor 07302 Jersey City, New Jersey, U.S.A
	Telephone	:	+1-551-430-6000
	E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

### 1.4 Emergency telephone number

+1-215-631-6999

## **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure, Category 1 Long-term (chronic) aquatic hazard, Category 1 H360D: May damage the unborn child. H372: Causes damage to organs through prolonged or repeated exposure. H410: Very toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms



Signal word

Hazard statements : H

÷

H360D May damage the unborn child.



## **Betamethasone Ointment Formulation**

Version 7.0	Revision Date: 06.04.2024	SDS Number: 1842048-00016	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017
		peated exposure.	lamage to organs through prolonged or re- c to aquatic life with long lasting effects.
Preca	utionary statements	P264 Wash ski P273 Avoid rele	pecial instructions before use. n thoroughly after handling. ease to the environment. tective gloves/ protective clothing/ eye protec- on.
		<b>Response:</b> P308 + P313 IF attention. P391 Collect sp	F exposed or concerned: Get medical advice/

Hazardous components which must be listed on the label: betamethasone

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Paraffin oil	8012-95-1 232-384-2	Asp. Tox. 1; H304 Aquatic Chronic 4; H413	>= 2,5 - < 10
betamethasone	378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Immune system, muscle, thymus	>= 0,025 - < 0,1

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Betamethasone Ointment Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.0	06.04.2024	1842048-00016	Date of first issue: 19.07.2017
			gland, Blood, Ad- renal gland) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 1.000 specific concentra- tion limit STOT RE 1; H372 >= 0,01 % Repr. 1B; H360D >= 0,01 %

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

## 4.2 Most important symptoms and effects, both acute and delayed

: May damage the unborn child.



## **Betamethasone Ointment Formulation**

Versio 7.0	on	Revision Date: 06.04.2024	-	9S Number: 42048-00016	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017
				Causes damage exposure.	to organs through prolonged or repeated
4.3 In	dicatio	on of any immediate	mec	lical attention and	d special treatment needed
Т	Freatmo	ent	:	Treat symptomat	cally and supportively.
SEC	TION	5: Firefighting meas	sur	es	
5.1 Ex	xtingu	ishing media			
S	Suitable	e extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (0 Dry chemical	
	Jnsuita nedia	ble extinguishing	:	None known.	
5.2 Sp	pecial	hazards arising from	the	substance or mi	xture
	Specific ighting	c hazards during fire-	:		n explosive mixtures with air. bustion products may be a hazard to health.
	Hazard ucts	ous combustion prod-	:	Carbon oxides	
5.3 Ao	dvice f	for firefighters			
	Special or firefi	protective equipment ighters	:		e, wear self-contained breathing apparatus. tective equipment.
	Specific ods	c extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do

## **SECTION 6:** Accidental release measures

## 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment.
	Follow safe handling advice (see section 7) and personal pro-
	tective equipment recommendations (see section 8).

## 6.2 Environmental precautions

Environmental precautions	:	Avoid release to the environment.
		Prevent further leakage or spillage if safe to do so.
		Retain and dispose of contaminated wash water.
		Local authorities should be advised if significant spillages
		cannot be contained.



## **Betamethasone Ointment Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.0	06.04.2024	1842048-00016	Date of first issue: 19.07.2017

## 6.3 Methods and material for containment and cleaning up

<ul> <li>Methods for cleaning up</li> <li>Sweep up or vacuum up spillage and collect i tainer for disposal.</li> <li>Local or national regulations may apply to relepsal of this material, as well as those materia employed in the cleanup of releases. You will mine which regulations are applicable.</li> <li>Sections 13 and 15 of this SDS provide inform certain local or national requirements.</li> </ul>	ials and items I need to deter-
--	------------------------------------

## 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

## 7.1 Precautions for safe handling

	Technical measures :	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
	Local/Total ventilation :	If sufficient ventilation is unavailable, use with local exhaust ventilation.
	Advice on safe handling :	Do not get on skin or clothing. Do not breathe dust, fume, gas, mist, vapours or spray. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the
	Hygiene measures :	environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
2	Conditions for safe storage, inc	luding any incompatibilities
	Requirements for storage :	Keep in properly labelled containers. Store locked up. Keep

## 7.2

Requirements for storage areas and containers	:	Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Advice on common storage	:	Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures



## Betamethasone Ointment Formulation

Version 7.0	Revision Date: 06.04.2024	SDS Number: 1842048-00016	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017
		Organic peroxide Explosives Gases	25
-	<b>c end use(s)</b> c use(s)	: No data available	•

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Petrolatum	8009-03-8	TWA (Vapour)	50 mg/m3	FOR-2011- 12-06-1358
		TWA (Mist and particles)	1 mg/m3	FOR-2011- 12-06-1358
Paraffin oil	8012-95-1	TWA (Vapour)	50 mg/m3	FOR-2011- 12-06-1358
		TWA (Mist and particles)	1 mg/m3	FOR-2011- 12-06-1358
betamethasone	petamethasone 378-44-9 TW		1 μg/m3 (OEB 4)	Internal
	Further infor	mation: Skin		
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef-	Value
			fects	
Paraffin oil	Workers	Inhalation	Long-term systemic	5 mg/m3
			effects	
	Workers	Inhalation	Short-term exposure	5 mg/m3
	Workers	Inhalation	Long-term local ef-	5 mg/m3
			fects	_
	Workers	Inhalation	Acute local effects	5 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9,33 mg/kg food

### 8.2 Exposure controls

### **Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted.



## **Betamethasone Ointment Formulation**

Version 7.0	Revision Date: 06.04.2024	SDS Number: 1842048-00016	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017			
Use closed processing systems or containment technologies.						
Personal protective equipment						

Personal protective equipment		
Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection Filter type	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387 Combined particulates and organic vapour type (A-P)

## **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Physical state	:	ointment
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Betamethasone Ointment Formulation**

Version 7.0	Revision Date: 06.04.2024	SDS Number:Date of last issue: 30.09.20231842048-00016Date of first issue: 19.07.2017	
Flas	sh point	: > 93,3 °C	
Auto	o-ignition temperature	: No data available	
Dec	omposition temperature	: No data available	
pН		: No data available	
	cosity /iscosity, kinematic	: Not applicable	
	ubility(ies) Water solubility	: No data available	
	ition coefficient: n- anol/water	: Not applicable	
Vap	our pressure	: No data available	
Rela	ative density	: No data available	
Der	sity	: No data available	
Rela	ative vapour density	: Not applicable	
	ticle characteristics Particle size	: No data available	
9.2 Othe	r information		
Exp	losives	: Not explosive	
Oxi	dizing properties	: The substance or mixture is not classified as oxidizing.	
Eva	poration rate	: Not applicable	

## **SECTION 10: Stability and reactivity**

	<b>Reactivity</b> Not classified as a reactivity haze	arc	i.
10.2	Chemical stability		
	Stable under normal conditions.		
10.3	Possibility of hazardous reacti	ior	IS
	Hazardous reactions :		Vapours may form explosive mixture with air. Can react with strong oxidizing agents.
10.4	Conditions to avoid		
	Conditions to avoid :		None known.



## **Betamethasone Ointment Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.0	06.04.2024	1842048-00016	Date of first issue: 19.07.2017

#### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### **10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of	:	Skin contact
exposure		Ingestion
		Eye contact

### Acute toxicity

Not classified based on available information.

### **Components:**

#### Paraffin oil:

Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity

### betamethasone:

Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg
		LD50 (Mouse): > 4.500 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): 0,4 mg/l Exposure time: 4 h

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

## Paraffin oil:

Species	:	Rabbit
Result	:	No skin irritation

### betamethasone:

Species	:	Rabbit
Result	:	Mild skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Betamethasone Ointment Formulation**

Version 7.0	Revision Date: 06.04.2024		DS Number: 42048-00016	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017
Comp	onents:			
Paraff	in oil:			
Specie Result	25	:	Rabbit No eye irritation	
betam	ethasone:			
Specie Result		:	Rabbit No eye irritation	
Respir	ratory or skin sensitis	satio	on	
	ensitisation assified based on availa	able	information.	
Respir	ratory sensitisation assified based on avail			
Comp	onents:			
betam	ethasone:			
Exposi Specie Result	ure routes es	::	Dermal Guinea pig Weak sensitizer	
	cell mutagenicity			
	assified based on avail onents:	able	information.	
	ethasone:			
	oxicity in vitro	:	Test Type: Bacter Result: negative	rial reverse mutation assay (AMES)
			Test Type: In vitro Result: negative	o mammalian cell gene mutation test
			Test Type: Chron Result: positive	nosome aberration test in vitro
Genoto	oxicity in vivo	:	Test Type: Mamn cytogenetic assay Species: Mouse Application Route Result: equivocal	: Oral
Germ o sessm	cell mutagenicity- As- ent	:	Weight of evidend cell mutagen.	ce does not support classification as a germ

### Carcinogenicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Betamethasone Ointment Formulation**

ersion 0	Revision Date: 06.04.2024	SDS Number: 1842048-0001	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017
	oductive toxicity Jamage the unborn chi	ld.	
	oonents:		
betar	nethasone:		
Effect ment	s on foetal develop-	Developme	abbit Route: Intramuscular ental Toxicity: LOAEL: 0,05 mg/kg body weight otoxicity, Malformations were observed.
		Developme	at Route: Subcutaneous ental Toxicity: LOAEL: 0,42 mg/kg body weight Iformations were observed.
		Developme	louse Route: Intramuscular ental Toxicity: LOAEL: 1 mg/kg body weight Iformations were observed.
Repro sessn	oductive toxicity - As- nent	: Clear evide animal exp	ence of adverse effects on development, based on eriments.
Not cl <b>STOT</b> Cause			or repeated exposure.
	oonents:		
Targe	<b>nethasone:</b> et Organs essment	Adrenal gla	and, Immune system, muscle, thymus gland, Blood, and mage to organs through prolonged or repeated
Repe	ated dose toxicity	exposure.	
•	oonents:		
	fin oil:		
Speci LOAE Applic	es	: Rat, femal : 161 mg/kg : Ingestion : 90 Days	•
betan	nethasone:		
Speci LOAE	es	: Rabbit : 0.05 % : Skin conta	ct

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Betamethasone Ointment Formulation**

Version 7.0	Revision Date: 06.04.2024	SDS Number: 1842048-00016	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017
	ure time Organs	: 10 - 30 d : Pituitary gland,	Immune system, muscle
Expos		: Rat : 0.05 % : Skin contact : 8 Weeks : thymus gland	
Expos		: Mouse : 0.1 % : Skin contact : 8 Weeks : thymus gland	
Expos		: Dog : 0,05 mg/kg : Oral : 28 d : Blood, thymus	gland, Adrenal gland

## Aspiration toxicity

Not classified based on available information.

## Components:

### Paraffin oil:

The substance or mixture is known to cause human aspiration toxicity hazards or has to be regarded as if it causes a human aspiration toxicity hazard.

### 11.2 Information on other hazards

#### Endocrine disrupting properties

#### Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### Experience with human exposure

#### **Components:**

#### betamethasone:

Inhalation	:	Target Organs: Adrenal gland
Skin contact	:	Symptoms: Redness, pruritis, Irritation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Betamethasone Ointment Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.0	06.04.2024	1842048-00016	Date of first issue: 19.07.2017

## **SECTION 12: Ecological information**

### 12.1 Toxicity

Paraffin oil:			
Toxicity to fish	:	:	LL50 (Scophthalmus maximus (turbot)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to daph aquatic inverteb	nnia and other : prates	:	EL50 (Acartia tonsa (Calanoid copepod)): > 100 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to alga plants	e/aquatic :	:	EL50 (Skeletonema costatum (marine diatom)): > 100 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
			NOELR (Skeletonema costatum (marine diatom)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
betamethason	e:		
Toxicity to daph aquatic inverted	nnia and other : prates	:	EC50 (Americamysis): > 50 mg/l Exposure time: 96 h
Toxicity to alga plants	e/aquatic :	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
			NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish icity)	(Chronic tox-	:	NOEC: 0,052 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
			NOEC: 0,07 µg/l Exposure time: 219 d Species: Oryzias latipes (Japanese medaka) Method: OECD Test Guideline 229

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Betamethasone Ointment Formulation**

Version 7.0	Revision Date: 06.04.2024		DS Number: 342048-00016	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017	
Toxicity to daphnia and other aquatic invertebrates (Chron-ic toxicity)		:	NOEC: 8 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211		
M-Fac toxicit	ctor (Chronic aquatic	:	1.000		
	stence and degradabil ata available	ity			
12.3 Bioad	ccumulative potential				
<u>Com</u>	oonents:				
Paraf	fin oil:				
	ion coefficient: n- ol/water	:	log Pow: > 4 Remarks: Calcula	ation	
	nethasone:				
	ion coefficient: n- ol/water	:	log Pow: 2,11		
<b>12.4 Mobi</b> No da	<b>lity in soil</b> ata available				
12.5 Resu	Its of PBT and vPvB as	sse	ssment		
Produ	uct:				
Asses	ssment	:	to be either persis	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of	
12.6 Endocrine disrupting properties					
Produ					
Asses	ssment	:	ered to have end REACH Article 57	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.	

## **SECTION 13: Disposal considerations**

## 13.1 Waste treatment methods

Product

: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in



## **Betamethasone Ointment Formulation**

Version 7.0	Revision Date: 06.04.2024		DS Number: 42048-00016	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017
Contaminated packaging		:	discussion with the waste disposal authorities. Do not dispose of waste into sewer. Empty containers should be taken to an approved waste har dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.	
SECTION	N 14: Transport inform	na	lion	
14.1 UN n	umber or ID number			
ADN		:	UN 3077	
ADR		:	UN 3077	
RID		:	UN 3077	
IMDG	ì	:	UN 3077	
ΙΑΤΑ		:	UN 3077	
14.2 UN p	roper shipping name			
ADN		:	ENVIRONMENT/ N.O.S. (betamethasone)	ALLY HAZARDOUS SUBSTANCE, SOLID,
ADR		:	ENVIRONMENT/ N.O.S. (betamethasone)	ALLY HAZARDOUS SUBSTANCE, SOLID,
RID		:	ENVIRONMENT N.O.S. (betamethasone)	ALLY HAZARDOUS SUBSTANCE, SOLID,
IMDG	ì	:	ENVIRONMENT N.O.S. (betamethasone)	ALLY HAZARDOUS SUBSTANCE, SOLID,
ΙΑΤΑ		:	Environmentally h (betamethasone)	nazardous substance, solid, n.o.s.
14.3 Trans	sport hazard class(es)			
			Class	Subsidiary risks
ADN		:	9	
ADR		:	9	
RID		:	9	
IMDG	ì	:	9	
ΙΑΤΑ		:	9	
14.4 Pack	ing group			
Class	ng group ification Code rd Identification Number	::	III M7 90	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Betamethasone Ointment Formulation**

Version 7.0	Revision Date: 06.04.2024		Number: 2048-00016	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017
Labe	ls	: 9	)	
Class Haza Labe	ing group sification Code ard Identification Number	: 9 : 9	Л7 90	
Class	ing group sification Code ard Identification Number Is	: N	II Л7 ЭО	
Labe	ing group	: II : 9 : F		
Pack aircra Pack	ing instruction (LQ) ing group	: Y : II	956 (956 II Aiscellaneous	
Pack ger a Pack	<b>(Passenger)</b> ing instruction (passen- ircraft) ing instruction (LQ) ing group	: Y : I	956 (956 II Aiscellaneous	
14.5 Envi	ronmental hazards			
<b>ADN</b> Envir	onmentally hazardous	: у	res	
<b>ADR</b> Envir	onmentally hazardous	: у	ves	
<b>RID</b> Envir	ronmentally hazardous	: у	ves	
<b>IMDO</b> Marir	G ne pollutant	: у	ves	
	(Passenger)	: у	/es	
	(Cargo) ronmentally hazardous	: у	res	
14.6 Spec	cial precautions for use	r		

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Betamethasone Ointment Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.0	06.04.2024	1842048-00016	Date of first issue: 19.07.2017

### 14.7 Maritime transport in bulk according to IMO instruments

#### Remarks : Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

	REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the fol- lowing entries should be considered: Number on list 75
			Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli- cable to the placing on the market or not. If you intend to use this product as tattoo ink, please contact your ven- dor.
-	REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
	REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
	Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable
	Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
	Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable
	Severa III: Directive 2012/18/ELL of the European Parlian	nent	and of the Council on the control of

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances. Quantity 1 Quantity 2

		Quantity I	Quantity Z
E1	ENVIRONMENTAL	100 t	200 t
	HAZARDS		

### Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

#### The components of this product are reported in the following inventories:

AICS :	not determined
--------	----------------

DSL not determined :

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Betamethasone Ointment Formulation**

Version 7.0	Revision Date: 06.04.2024	SDS Number: 1842048-00016	Date of last issue: 30.09.2023 Date of first issue: 19.07.2017				
IECS	C	: not determined	not determined				
15.2 Chei	nical safety assessm	ent					
A Chemic	al Safety Assessment	has not been carried o	but.				
SECTIO	N 16: Other informa	tion					
Other information			Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.				
Full	text of H-Statements						
H304		-	May be fatal if swallowed and enters airways.				
H330 H360			Fatal if inhaled. May damage the unborn child.				
H372		: Causes damag	: Causes damage to organs through prolonged or repeated				
			exposure.				
	H410:Very toxic to aquatic life with long lasting effects.H413:May cause long lasting harmful effects to aquatic						
Full	text of other abbrevia	tions					
	e Tox.	: Acute toxicity					
	itic Chronic		onic) aquatic hazard				
Asp. Repr		: Aspiration haza : Reproductive to					
STO			organ toxicity - repeated exposure				
FOR	-2011-12-06-1358		pational Exposure limits				
FOR TWA	-2011-12-06-1358 /	: Long term expo	: Long term exposure limit				
ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -							

DSL - Domestic Substances List (Canada); ECHA German Institute for Standardisation: European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of



## Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
7.0	06.04.2024	1842048-00016	Date of first issue: 19.07.2017

Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### Further information

Classification of the mixture:	Classification procedure:
Sources of key data used to : compile the Safety Data Sheet	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the m	Classification proc	
Repr. 1B	H360D	Calculation method
STOT RE 1	H372	Calculation method
Aquatic Chronic 1	H410	Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN